Zoe Moodie, Shuying Sue Li, Elena E Giorgi, LaTonya D Williams, One Dintwe, Lindsay N Carpp, Shiyu Chen, Kelly E Seaton, Sheetal S Sawant, Lu Zhang, Jack Heptinstall, Shuying Liu, Nicole Grunenberg, Frank Tomaka, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Julie A Ake, Sandhya Vasan, Giuseppe Pantaleo, Ian Frank, Lindsey R Baden, Paul A Goepfert, Michael Keefer, Mike Chirenje, Mina C Hosseinipour, Kathryn Mngadi, Fatima Laher, Nigel Garrett, Linda-Gail Bekker, Stephen De Rosa, Erica Andersen-Nissen, James G Kublin, Shan Lu, Peter B Gilbert, Glenda E Gray, Lawrence Corey, M Juliana McElrath, Georgia D Tomaras
{"title":"在13项HIV疫苗试验中，多价DNA引物与匹配的多价蛋白/GLA-SE增强方案引发了最强大和广泛的IgG和IgG3 V1V2结合抗体和CD4+ T细胞反应。","authors":"Zoe Moodie, Shuying Sue Li, Elena E Giorgi, LaTonya D Williams, One Dintwe, Lindsay N Carpp, Shiyu Chen, Kelly E Seaton, Sheetal S Sawant, Lu Zhang, Jack Heptinstall, Shuying Liu, Nicole Grunenberg, Frank Tomaka, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Julie A Ake, Sandhya Vasan, Giuseppe Pantaleo, Ian Frank, Lindsey R Baden, Paul A Goepfert, Michael Keefer, Mike Chirenje, Mina C Hosseinipour, Kathryn Mngadi, Fatima Laher, Nigel Garrett, Linda-Gail Bekker, Stephen De Rosa, Erica Andersen-Nissen, James G Kublin, Shan Lu, Peter B Gilbert, Glenda E Gray, Lawrence Corey, M Juliana McElrath, Georgia D Tomaras","doi":"10.1080/22221751.2025.2485317","DOIUrl":null,"url":null,"abstract":"<p><p>Developing an effective HIV vaccine is a momentous challenge. An exceptionally wide range of candidate HIV vaccines have been tested, yet many were poorly immunogenic, and of the select few that advanced into efficacy trials, only one demonstrated any efficacy. Here we report the results of the largest-scale cross-protocol immunogenicity comparison to date: 13 HIV vaccine trials (including 36 vaccine regimens) conducted across nine countries worldwide, strengthened by standardized trial designs, validated assays in centralized laboratories, and harmonized immunogenicity endpoints - providing an objective approach to identify the HIV vaccine candidate(s) with the best immunogenicity. A polyvalent DNA prime + protein boost regimen (HVTN 124) including Env immunogens of four subtypes, matched between prime and boost, achieved the best anti-V1V2 antibody responses by a large margin and also induced high CD4+ T-cell responses - two key immune responses implicated in HIV vaccine protection. Our results provide strong support to test this promising HIV vaccine design in more advanced phase clinical trials and will also guide the future design of additional HIV vaccines.<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT01799954..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02109354..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02404311..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02207920..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02296541..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT03284710..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02915016..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02997969..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT03122223..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT03409276..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02968849..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT03060629..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT00223080..</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":"14 1","pages":"2485317"},"PeriodicalIF":7.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980190/pdf/","citationCount":"0","resultStr":"{\"title\":\"A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials.\",\"authors\":\"Zoe Moodie, Shuying Sue Li, Elena E Giorgi, LaTonya D Williams, One Dintwe, Lindsay N Carpp, Shiyu Chen, Kelly E Seaton, Sheetal S Sawant, Lu Zhang, Jack Heptinstall, Shuying Liu, Nicole Grunenberg, Frank Tomaka, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Julie A Ake, Sandhya Vasan, Giuseppe Pantaleo, Ian Frank, Lindsey R Baden, Paul A Goepfert, Michael Keefer, Mike Chirenje, Mina C Hosseinipour, Kathryn Mngadi, Fatima Laher, Nigel Garrett, Linda-Gail Bekker, Stephen De Rosa, Erica Andersen-Nissen, James G Kublin, Shan Lu, Peter B Gilbert, Glenda E Gray, Lawrence Corey, M Juliana McElrath, Georgia D Tomaras\",\"doi\":\"10.1080/22221751.2025.2485317\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Developing an effective HIV vaccine is a momentous challenge. An exceptionally wide range of candidate HIV vaccines have been tested, yet many were poorly immunogenic, and of the select few that advanced into efficacy trials, only one demonstrated any efficacy. Here we report the results of the largest-scale cross-protocol immunogenicity comparison to date: 13 HIV vaccine trials (including 36 vaccine regimens) conducted across nine countries worldwide, strengthened by standardized trial designs, validated assays in centralized laboratories, and harmonized immunogenicity endpoints - providing an objective approach to identify the HIV vaccine candidate(s) with the best immunogenicity. A polyvalent DNA prime + protein boost regimen (HVTN 124) including Env immunogens of four subtypes, matched between prime and boost, achieved the best anti-V1V2 antibody responses by a large margin and also induced high CD4+ T-cell responses - two key immune responses implicated in HIV vaccine protection. Our results provide strong support to test this promising HIV vaccine design in more advanced phase clinical trials and will also guide the future design of additional HIV vaccines.<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT01799954..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02109354..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02404311..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02207920..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02296541..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT03284710..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02915016..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02997969..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT03122223..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT03409276..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02968849..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT03060629..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT00223080..</p>\",\"PeriodicalId\":11602,\"journal\":{\"name\":\"Emerging Microbes & Infections\",\"volume\":\"14 1\",\"pages\":\"2485317\"},\"PeriodicalIF\":7.5000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980190/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Emerging Microbes & Infections\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/22221751.2025.2485317\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Emerging Microbes & Infections","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/22221751.2025.2485317","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials.
Developing an effective HIV vaccine is a momentous challenge. An exceptionally wide range of candidate HIV vaccines have been tested, yet many were poorly immunogenic, and of the select few that advanced into efficacy trials, only one demonstrated any efficacy. Here we report the results of the largest-scale cross-protocol immunogenicity comparison to date: 13 HIV vaccine trials (including 36 vaccine regimens) conducted across nine countries worldwide, strengthened by standardized trial designs, validated assays in centralized laboratories, and harmonized immunogenicity endpoints - providing an objective approach to identify the HIV vaccine candidate(s) with the best immunogenicity. A polyvalent DNA prime + protein boost regimen (HVTN 124) including Env immunogens of four subtypes, matched between prime and boost, achieved the best anti-V1V2 antibody responses by a large margin and also induced high CD4+ T-cell responses - two key immune responses implicated in HIV vaccine protection. Our results provide strong support to test this promising HIV vaccine design in more advanced phase clinical trials and will also guide the future design of additional HIV vaccines.Trial registration: ClinicalTrials.gov identifier: NCT01799954..Trial registration: ClinicalTrials.gov identifier: NCT02109354..Trial registration: ClinicalTrials.gov identifier: NCT02404311..Trial registration: ClinicalTrials.gov identifier: NCT02207920..Trial registration: ClinicalTrials.gov identifier: NCT02296541..Trial registration: ClinicalTrials.gov identifier: NCT03284710..Trial registration: ClinicalTrials.gov identifier: NCT02915016..Trial registration: ClinicalTrials.gov identifier: NCT02997969..Trial registration: ClinicalTrials.gov identifier: NCT03122223..Trial registration: ClinicalTrials.gov identifier: NCT03409276..Trial registration: ClinicalTrials.gov identifier: NCT02968849..Trial registration: ClinicalTrials.gov identifier: NCT03060629..Trial registration: ClinicalTrials.gov identifier: NCT00223080..
期刊介绍：
Emerging Microbes & Infections is a peer-reviewed, open-access journal dedicated to publishing research at the intersection of emerging immunology and microbiology viruses.
The journal's mission is to share information on microbes and infections, particularly those gaining significance in both biological and clinical realms due to increased pathogenic frequency. Emerging Microbes & Infections is committed to bridging the scientific gap between developed and developing countries.
This journal addresses topics of critical biological and clinical importance, including but not limited to:
- Epidemic surveillance
- Clinical manifestations
- Diagnosis and management
- Cellular and molecular pathogenesis
- Innate and acquired immune responses between emerging microbes and their hosts
- Drug discovery
- Vaccine development research
Emerging Microbes & Infections invites submissions of original research articles, review articles, letters, and commentaries, fostering a platform for the dissemination of impactful research in the field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
